« Back
Home /
PNU-159682

PNU-159682

Item no.	HY-16700-25mg
Manufacturer	MedChem Express
CASRN	202350-68-3
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	98.57
Citations	[1]Quintieri L, et al. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res. 2005 Feb 15;11(4):1608-17.\|[2]Cazzamalli S, et al. Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma. Mol Cancer Ther. 2016 Dec;15(12):2926-2935.\|[3]Pengxuan Zhao, et al. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B. 2020 Sep;10(9):1589-1600.\|[4]Joanne Lundy, Interim data: Phase I/IIa study of EGFR-targeted EDV nanocells carrying cytotoxic drug PNU-159682 (E-EDV-D682) with immunomodulatory adjuvant EDVs carrying α-galactosyl ceramide (EDV-GC) in patients with recurrent, metastatic pancreatic cancer. GASTROINTESTINAL CANCER—GASTROESOPHAGEAL, PANCREATIC, AND HEPATOBILIARY
Smiles	COC1=C(C(C(C(O)=C([C@@H](O[C@H]2C[C@H]3[C@H](O[C@H]4N3CCO[C@@H]4OC)[C@H](C)O2)C[C@@](C(CO)=O)(O)C5)C5=C6O)=C6C7=O)=O)C7=CC=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	ADC Related
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	ADC Cytotoxin; Topoisomerase
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, stored under nitrogen)
Molecular Weight	641.62
Product Description	PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Isoform	Daunorubicins/Doxorubicins; Topo I
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-16700-25mg-safety-datasheet.pdf